05:00 PM EDT, 06/17/2026 (MT Newswires) -- Legend Biotech ( LEGN ) said late Wednesday it has started an underwritten public offering of $225 million of American depositary shares.

Legend said it plans to grant its underwriters a 30-day option to buy up to an additional 15% of the ADS sold in the public offering.

Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are joint book-running managers for the offering.